Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 15/20 | 0.64 |
| ▸ | CA1 | P00915 | 15/20 | 0.64 |
| ▸ | CA2 | P00918 | 15/20 | 0.64 |
| ▸ | CA4 | P22748 | 15/20 | 0.64 |
| ▸ | CA7 | P43166 | 15/20 | 0.64 |
| ▸ | CA9 | Q16790 | 15/20 | 0.64 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4648066 | 0.75 | CA12 (0.49) | CA12CA1CA2CA4CA7 | |
| SCHEMBL9278777 | 0.75 | CA12 (1.00) | CA12CA1CA2CA4CA7 | |
| SCHEMBL18125263 | 0.75 | CA12 (1.00) | CA12CA1CA2CA4CA7 | |
| SCHEMBL4128481 | 0.73 | RET (0.57) | CA12CA1CA2CA4CA7 | |
| SCHEMBL4691064 | 0.71 | CA12 (0.44) | CA12CA1CA2CA4CA7 | |
| SCHEMBL10636828 | 0.70 | CA12 (0.62) | CA12CA1CA2CA4CA7 | |
| SCHEMBL8286607 | 0.70 | CA12 (0.53) | CA12CA1CA2CA9 | |
| SCHEMBL29766441 | 0.67 | CA12 (1.00) | CA12CA1CA2CA4CA7 | |
| SCHEMBL3493374 | 0.67 | CA12 (1.00) | CA12CA1CA2CA4CA7 | |
| SCHEMBL18953724 | 0.67 | CREBBP (0.39) | CA12CA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1631559-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20060122173-A1 | Il-8 receptor antagonists | BUSCH-PETERSEN JAKOB | 2006-06-08 | — | — | US | disclosed |
| EP-1631559-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-2005000231-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122173-A1 | Il-8 receptor antagonists | CXCL8, CCR8, IL1RN | CA12 3361/4885CA1 3382/4885CA2 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.